Table 3.
Clinical details of children with cancer and lethal outcome because of SARS-CoV-2 infection.
| Age (y)/sex | Country | Malignancy | Last anticancer treatment | Comorbidity | ANC/ALC at diagnosis of SARS-CoV-2 (per mm3) | Coinfection | Mechanical ventilation | Antiviral treatment | Time between SARS-CoV-2 diagnosis and death (days) |
|---|---|---|---|---|---|---|---|---|---|
| 6/female | Russia | Acute leukaemia | HSCT >6 months | Kaposi sarcoma | 3900/780 | No | Yes (ARDS) | Ribavirin, lopinavir, hydroxychloroquine | 18 |
| 9/female | Brazil | Acute leukaemia | 5 days before | Steroid-induced adrenal insufficiency | 0/0 | No | Yes (ARDS) | No | 21 |
| 11/female | Brazil | Brain tumour | >30 days before | Steroid-induced adrenal insufficiency, obesity | 3680/3320 | No | Yes (ARDS) | Oseltamivir | 9 |
| 11/female | Brazil | Brain tumour | >30 days before | Steroid-induced adrenal insufficiency, obesity, chronic neurological problems | 7080/2730 | No | Yes (ARDS) | No | 6 |
HSCT, haematopoietic stem cell transplantation; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; ARDS, acute respiratory distress syndrome.